However, G3 enhanced tumor cell migration to the wounding areas was significantly inhibited by EGFR antagonist AG 1478 but not by MEK inhibitor PD 98059 (Fig. 6a, Fig. 6b), suggesting that versican G3 enhanced breast cancer cell motility through EGFR signaling in a mechanism that did not involve the ERK downstream pathway. This evidence concerns the gene MAP2K7 and breast cancer.